Lundbeck to Acquire Prexton Therapeutics for $1.1 billion

Knobbe Martens

Knobbe Martens

Lundbeck Pharmaceutical Company, headquartered in Denmark, recently announced the acquisition of Prexton Therapeutics B.V. for $1.1 billion (U.S.)[1].  Lundbeck is a publicly traded company focusing on psychiatric and neurological disorders[2].  Prexton, founded in 2012 and based in the Netherlands and Switzerland, focuses on developing drugs to improve the quality of life of those who suffer from Parkinson’s disease and other disorders[3].  Prexton is a spinout of Merck Ventures[4]. 

Parkinson’s disease is a neurological condition affecting more than one percent of the population over 60[5].  The disease occurs due to degeneration of dopaminergic brain cells[6].  The main symptoms are: tremors at rest, slowness of movement, limb rigidity and gait and balance problems.   

Prexton’s pipeline focuses on new chemical entities targeting mGluR4 receptors[7].  According to the press release, the acquisition of Prexton allows Lundbeck to obtain global rights to Foliglurax, Prexton’s lead chemical compound.  Foliglurax is currently undergoing phase II clinical trials of 165 patients in Europe for treatment of Parkinson’s  disease[8].    

Foliglurax works by stimulating the mGluR4 glutamatergic receptor that leads to reduced tremors, muscle rigidity, and uncontrolled movements.  According to the press release, Lundbeck is paying approximately $122 million in cash (U.S.) and $985 million (U.S.) in development and sales milestones for Prexton.  



DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Knobbe Martens | Attorney Advertising

Written by:

Knobbe Martens

Knobbe Martens on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.